PubMed Health⌕ Search

Biomedical subjects

C Giberti

Publications and source records attributed to C Giberti.

At least 37 records · Page 2Linked to original sources
PubMed1987

Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.

Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the depot formulation of D-TRP-6 LH-RH ("Decapeptyl") for up to 33 months. Serum testosterone (T) levels were significantly reduced to castration levels within 4 weeks and maintained persistently low. Similarly, LH levels were decreased, although they remained in the normal range. Stimulation tests with either Gn-RH or HCG in course of treatment showed the achievement of a complete pituitary desensitization and almost a complete down-regulation of testicular LH receptors. Of 88 patients evaluable for response, about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained without major side effects. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.

Acid Phosphatase↗
PubMed1987

Value of computerized tomography and ultrasonography in the preoperative diagnosis of renal cell carcinoma extending into the inferior vena cava.

During a 15-year period, 34 patients with renal cell carcinoma extending into the inferior vena cava were submitted to radical ablative surgery at our institution. 8 patients had caval tumor thrombus (TT) extension at the level of the renal veins, 17 had infrahepatic, 8 retrohepatic and 1 atrial TT extension. Cavography, computerized tomography (CT) and ultrasonography (US) were performed preoperatively on 34, 24 and 16 of these 34 patients, respectively. The sensitivity of the techniques used in diagnosing caval involvement was 100, 97 and 87.5% for US, cavography and CT, respectively. The upper limits of TT were clearly detected by US, CT and cavography in 100, 95 and 76% of diagnosed cases, respectively. From this study it appears that US and CT have a sensitivity comparable to cavography in the detection of caval TT. However, US and CT allow a more precise delineation of the upper limits of TT if compared to cavography. This implies that the role of cavography in diagnosing caval TT and its upper limits must be reappraised in light of the progress of noninvasive outpatient procedures.

Adult↗
PubMed1986

Suppression of testicular androgenesis by D-tryptophan-6-luteinizing hormone-releasing hormone does not affect TSH secretion in male subjects.

Basal and TRH-stimulated TSH secretion was evaluated in six patients suffering from prostatic cancer, before and after antiandrogenic treatment performed using a long-acting LHRH analogue, D-Trp-6-LHRH. Although serum testosterone values dropped to minimal levels after treatment, TSH secretion remained unchanged. Observed results suggest that pharmacological castration does not affect the regulatory mechanisms involved in the control of TSH secretion.

Aged↗
PubMed1986

Surgical management of renal cell carcinoma with vena cava tumor thrombus.

The results of the surgical management of 28 patients with renal cell carcinoma extending into the inferior vena cava have been analyzed. 8 patients had caval tumor thrombus extension at the level of the renal veins, 14 had infrahepatic, 5 retrohepatic and 1 atrial tumor thrombus extension. The caval wall was infiltrated by tumor in 7 cases. 9 patients had metastases. Lymph node involvement was seen in 9 patients. Life-table analysis of all 28 patients revealed on overall probability of survival of 32 and 9% at 2 and 5 years, respectively. The patients with caval involvement alone (N0M0) had a 2-year survival rate of 69%. Those with distant metastases or caval infiltration had a 2-year survival of 27 and 0% (p = NS). The level of caval tumor thrombus extension had a statistically insignificant influence on the survival of patients. In fact the 2-year survival rates of patients with caval thrombus at the level of the renal veins, below the large hepatic veins and above the large hepatic veins were 30, 36 and 32%, respectively. Our statistical data demonstrate that caval involvement has a very negative impact on the prognosis of patients with renal cancer.

Actuarial Analysis↗
PubMed1986

Treatment of prostatic cancer with a depot form of a luteinizing hormone-releasing hormone analogue.

Chronic administration of a depot form of D-Trp6 luteinizing hormone-releasing hormone (LH-RH), an LH-RH analogue (3 mg i.m. every 28 days for a mean period of 9.1 months), to 14 patients with locally extended or metastatic cancer of the prostate provided a good degree of disease control. After a slight and transient increase in gonadotropin secretion, the peptide induced a sharp and long-lasting inhibition of both gonadotropin and testosterone secretion, contemporaneously with clinical improvement and without any important side effects. These results are comparable to those recorded by others after daily administration of LH-RH analogues.

Acid Phosphatase↗
PubMed1985

Results of radical cystectomy for primary bladder cancer. Retrospective study of more than 200 cases.

During a seven-year period 202 patients with primary bladder cancer had radical cystectomy with bilateral pelvic lymphadenectomy and urinary diversion. Lymph node metastases were found in 28.7 per cent. No significant differences in overall survival owing to age were apparent. Only extension and grade of histopathologic differentiation of the tumor proved to be an important prognostic factor. The five-year survival rates for pT1, pT2, pT3, and pT4 tumors were 76, 56, 19, and 0 per cent, respectively. In patients with deep invasive (T3 and T4) tumors no significant differences of survival rate depending on N and M categories were found. Nevertheless in pT3 tumors the probability of remaining alive was significantly decreased in those patients with histologic grade 3 compared with grade 2 tumors (P less than 0.01). The prognosis for patients submitted to radical cystectomy for bladder cancer has been classified as good: tumors confined to superficial muscle (pT1 and pT2); intermediate: tumors mildly differentiated infiltrating the deep muscle (pT3/G2); fairly poor: tumors undifferentiated infiltrating deep muscle (pT3/G3); and poor: adjacent invasive bladder tumors (pT4).

Adult↗
PubMed1983

Results of radical nephrectomy with extensive lymphadenectomy for renal cell carcinoma.

Radical nephrectomy with extensive lymphadenectomy was performed by the same surgeon on 104 consecutive patients with renal cell carcinoma. No significant differences in over-all survival owing to age, sex and preoperative embolization were noted. Only extension of the disease proved to be important as a prognostic factor. In the light of the statistical analysis of this variable the prognosis for patients with renal cell carcinoma has been classified as 1) good--patients with tumors confined to the kidney, 2) intermediate--patients with perirenal fat involvement, lymph node metastases and venous extension, and 3) poor--patients with distant metastases.

Adenocarcinoma↗
PubMed1983

Cytogenetic analysis of transitional cell carcinoma of the bladder. Clinical implications.

Cytogenetic analysis of resected bladder tumors was performed in 30 patients. None of these patients had previous irradiation or chemotherapy. Direct chromosome preparations were made. Of the 30 preparations, 20 had chromosome abnormalities. We have observed a good correlation between the chromosome abnormalities and the stage/grade of the tumors. Patients were followed from 3 to 23 months. During this period, 61% of the patients with noninvasive or submucosal invasive bladder tumors and chromosome abnormalities have had recurrences. The existence of a good correlation between chromosomal abnormalities and the capacity of the neoplasm to recur was confirmed.

Aged↗
PubMed1983

[Chromosomal analysis of primary superficial tumors of the bladder].

Cytogenetic analysis of resected bladder tumors was performed in 32 patients. None of these patients had previous irradiation or chemotherapy. Direct chromosome preparations were made. Of the 32 preparations, 22 had chromosome abnormalities. We have observed a good correlation between the chromosome abnormalities and the Stage/Grade of the tumors. Patients were followed from 6 to 33 months. During this period, 82% of the patients with noninvasive or submucosal invasive bladder tumors and chromosome abnormalities have had recurrences. The existence of a good correlation between chromosomal abnormalities and the capacity of the neoplasm to recur was confirmed.

Aged↗
PubMed1981

[Surgical treatment of renal adenocarcinoma with neoplastic thrombosis of the inferior vena cava].

Personal experience in the surgical management of 15 cases of renal adenocarcinoma with neoplastic thrombosis of the vena cava inferior is described, and an account is given of the procedures adopted in accordance with the degree of endocavitary extension of the tumour. Emphasis is also placed on the need to ensure, as in all cases of nephrectomy for tumours, "neoplastic asepsis" by means of a preliminary vascular stage with the compartment intact. For this purpose, it is felt that sufficient preoperative angiographic evaluation of the intracavitary tumour is essential, coupled with absolute intraoperative control of the vena cava and/or right atrium proximally to the thrombus, to prevent the intraoperative mobilisation of neoplastic embolisms.

Adenocarcinoma↗
PubMed1981

Prolactin secretion in benign prostatic hypertrophy.

Prolactin secretion was evaluated in 22 patients with benign prostatic hypertrophy, before and after thyrotropin-releasing hormone stimulation. Increased prolactin reserve was found. In 11 patients, in whom the test was performed twice, the prolactin response after surgery was higher than in the pre-surgical test. The possible role of prolactin in the genesis of benign prostatic hypertrophy is discussed.

Aged↗
PubMed1980

[Renal adenocarcinoma with neoplastic thrombus in the inferior vena cava. Prognosis and operative risk].

10 cases of renal adenocarcinoma invading the lower vena cava and subjected at the Genoa urology clinic to radical nephrectomy and cavotomy, with thrombectomy or resection of the vena cava, are reviewed. Of 5 patients who did not present long-term metastasis, 2 are alive and in good condition at 30 and 64 months, one died from myocardial infarction after 34 months, and two died in the postoperative course from respectively renal insufficiency and myocardial infarction. In patients presenting long-term metastasis at the moment of surgery, results were poor: four patients died from 4 to 7 months later and only one patient, with bone metastasis, is alive after 33 months.

Adenocarcinoma↗
PubMed1980

Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy--5-year follow-up.

We report the results from 106 patients with extracapsular (stage C) or widespread (stage D) prostatic cancer, who were treated with cyproterone acetate and orchiectomy and followed for 5 years. As controls we used 40 patients, chosen at random, with stage C and stage D cancer of the prostate gland who were treated with stilbestrol and orchiectomy. The survival rate is improved in patients treated with cyproterone acetate and orchiectomy compared to the patients treated with stilbestrol and orchiectomy. Treatment with cyproterone seems more effective in those patients with low-stage and low-grade prostatic cancer. The side effects of this therapy are less and milder than those described in estrogenic treatment alone or with orchiectomy.

Adult↗